Evidence map›Paper›PMID 29100278›Full record

ArticleOncotarget2017

Somatic mutations in salivary duct carcinoma and potential therapeutic targets.

Timothy K Khoo, Bing Yu, Joel A Smith, Angus J Clarke, Peter P Luk, Christina I Selinger, Kate L Mahon, Spiridoula Kraitsek, Carsten Palme, Michael J Boyer and 5 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Molecular patterns in salivary duct carcinoma identify prognostic subgroups.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Timothy K Khoo *Central Clinical School, The University of Sydney, Australia.
Bing Yu *Central Clinical School, The University of Sydney, Australia.
Joel A SmithThe Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, Australia.
Angus J ClarkeCentral Clinical School, The University of Sydney, Australia.
Peter P LukDepartment of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia.
Christina I SelingerDepartment of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia.
Kate L MahonCentral Clinical School, The University of Sydney, Australia.
Spiridoula KraitsekDepartment of Medical Genomics, Royal Prince Alfred Hospital, Sydney, Australia.
Carsten PalmeCentral Clinical School, The University of Sydney, Australia.
Michael J BoyerCentral Clinical School, The University of Sydney, Australia.
Marcel E DingerKinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia.
Mark J CowleyKinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia.
Sandra A O'TooleCentral Clinical School, The University of Sydney, Australia.
Jonathan R Clark *Central Clinical School, The University of Sydney, Australia.
Ruta Gupta *Central Clinical School, The University of Sydney, Australia.
Chris O’Brien Lifehouse · AURoyal Prince Alfred Hospital · AUUniversity of Sydney · AUGarvan Institute of Medical Research · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSalivary duct carcinomas (SDCa) are rare highly aggressive malignancies. Most patients die from distant metastatic disease within three years of diagnosis. There are limited therapeutic options for disseminated disease.

results11 cases showed androgen receptor expression and 6 cases showed HER2 amplification. 6 Somatic mutations with additional available targeted therapies were identified: MATERIALS AND

methodsSomatic mutation analysis was performed on DNA extracted from 15 archival cases of SDCa using the targeted Illumina TruSeq Amplicon Cancer Panel. Potential targetable genetic alterations were identified using extensive literature and international somatic mutation database (COSMIC, KEGG) search. Immunohistochemistry for androgen receptor and immunohistochemistry and fluorescent

conclusionsSDCa show multiple somatic mutations, some that are amenable to pharmacologic manipulation and others that confer resistance to treatments currently under investigation. These findings emphasize the need to develop testing and treatment strategies for SDCa.

Indexed as

androgen receptorHER2salivary duct carcinomasomatic mutation analysistargeted therapies

Identifiers

PMID29100278
PMCPMC5652672
OpenAlexW2618204257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.